NAD+ Dosing Protocol: Cellular Energy Guide
Also known as: Nicotinamide Adenine Dinucleotide, Cellular Coenzyme
Studied in published research — not a medical recommendation. Primary protocol (Subcutaneous Injection Protocol): 50-100 mg, Once weekly.
Once weekly
Research-reported range (no primary dosing study). Start at 50mg and titrate up based on tolerance
Subcutaneous
Published peer-reviewed research & clinical protocols
No verified human half-life on file for this compound
A vial is powder until you add bacteriostatic water. Change the vial size or water volume below to see the exact unit mark on your syringe.
All U-100: 100 units = 1 mL. 0 doses in the vial at the low end.
Save NAD+ to your personal protocol list to log your custom dosage, syringe units, ON/OFF cycle dates, and lab notes across devices.
NAD+ supplier & $/mg comparison.
At a Glance · 2026 FDA / 503A / WADA / Evidence Profile
EDUCATIONAL AND RESEARCH REFERENCE ONLY — NOT MEDICAL ADVICE. NAD+ is not FDA approved for human use (unless specified above). This information does not constitute medical advice.
Overview
NAD+ is a critical coenzyme found in all living cells that plays essential roles in cellular energy metabolism, DNA repair, and signaling pathways. NAD+ levels decline with age.
Mechanisms of Action
- Essential cofactor for sirtuins (SIRT1-7) - longevity genes
- Critical for mitochondrial ATP production
- Substrate for PARP enzymes in DNA repair
- Activates sirtuins to improve metabolic function
Research Protocols
Summaries of published research. For educational purposes only.
| Protocol Name | Source | Dose | Frequency | Duration | Route | Evidence | Link | Save |
|---|---|---|---|---|---|---|---|---|
| Subcutaneous Injection Protocol | reported protocol | 50-100 mg | Once weekly | 4-12 weeks | Subcutaneous | human | — | |
| IV Infusion Protocol | reported protocol | 250-1000 mg | Weekly or bi-weekly | 4-6 weeks initial series | Intravenous infusion (2-4 hours) | human | — |
Systemic Inflammation, Tissue Repair & Immune Biomarker Panel (NAD+)
Objective inflammatory, hematologic, and trace-mineral markers to quantify connective-tissue recovery, cytokine resolution, and organ safety.
hs-CRP (High-Sensitivity C-Reactive Protein)
Day 0 + Wk 6–8Why track at baseline: Quantifies baseline systemic IL-6/NF-κB inflammatory burden from tendon, joint, gut, or vascular injury.
Week 6–8 check: Target <1.0 mg/L (optimal <0.5 mg/L) by Week 6–8 as tissue inflammation resolves.
ESR (Sedimentation Rate) & Ferritin
Day 0 + Wk 6–8Why track at baseline: Tracks chronic connective-tissue and autoimmune/mucosal inflammatory activity alongside iron stores.
Week 6–8 check: Downward trend in ESR confirming structural resolution rather than temporary analgesic masking.
CBC with Differential (WBC, Neutrophil/Lymphocyte Ratio)
Day 0 + Wk 6–8Why track at baseline: Evaluates innate/adaptive immune balance (especially for Thymosin Alpha-1, Thymosin Beta-4, LL-37 & KPV).
Week 6–8 check: Balanced lymphocyte count and improved Neutrophil-to-Lymphocyte Ratio (NLR 1.2–2.0).
CMP (Liver/Kidney) + Serum Copper & Zinc Ratio
Day 0 + Wk 6–8Why track at baseline: Verifies baseline hepatic/renal function and checks Copper:Zinc balance before GHK-Cu / GLOW / KLOW protocols.
Week 6–8 check: Maintain 1:1 to 1.2:1 Zinc-to-Copper equilibrium and normal transaminases/creatinine.
Related Studies
Thus, NAD+ restoration coordinates RNA splicing fidelity with downstream proteostatic systems, establishing a metabolic - transcriptional checkpoint for neuronal quality control. This finding expands the paradigm of autophagy regulation, positioning metabolic splice-switching as a crucial mechanism to maintain proteostasis and suggesting new strategies to combat aging-related neurodegenerative diseases.
Limitations: No placebo control reported.
At 1 month, the NAD+ group demonstrated a significantly greater improvement in LVEF compared to the placebo group (45.44 ± 8.55% vs. 42.44 ± 9.09%, p = 0.024).
Limitations: Standard limitations apply. Check original paper for full discussion.
In addition, the inhibition of NAD+-degrading enzymes (e.g., poly ADP-ribose polymerase (PARP), cluster of differentiation 38 (CD38), and selective androgen receptor modulators (SARMs)) increases the tissue intracellular NAD+ content, and supplementation with NAD+ precursors (e.g., β-nicotinamide mononucleotide (NMN), nicotinamide riboside, etc.) also significantly elevates myocardial NAD+ levels to ameliorate heart failure. This study provides a theoretical basis for understanding the central role of NAD+ in mitochondrial homeostasis and for the development of targeted therapies for heart failure.
Limitations: No placebo control reported. Review article — no new primary data.
In the probe test of the Morris water maze, the cuprizone group spent a significantly smaller proportion of time in the target quadrant than the control group did (16.32% vs. 31.66%, p = 0.006).
Limitations: Animal study only — human translation uncertain.
We revealed a depression in open-field activity and Y-maze performance with NADH supplementation, an indicator of cognitive recovery in rodents. The broad implications of NAD+ in aging are likely to shape supplementation trends, highlighting the importance of understanding the potential influence of administering NAD+ on anesthetic sensitivity and recovery.
Limitations: Animal study only — human translation uncertain.
In this study, we investigate the effect of acute supplementation of nicotinamide mononucleotide, a direct precursor of Nicotinamide adenine dinucleotide, in a lipopolysaccharide-induced delirium mouse model. While Nicotinamide adenine dinucleotide did not rescue the delirium-like sickness behavior and metabolic dysfunction in mice, a comprehensive cytokine profile analysis did reveal rescue of plasma IFNγ levels by nicotinamide mononucleotide supplementation and partial improvement on the levels of IL-12p40, RANTES, LIX, and IL-17 which were sex-dependent.
Limitations: Animal study only — human translation uncertain.
Nicotinamide adenine dinucleotide supplementation fails to enhance anesthetic recovery in rodents.
Animal StudyInstead, there was a depression in open-field activity and no change in Y-maze performance with NADH supplementation, indicators of locomotive and cognitive recovery in rodents. The broad implications of NAD+ in aging are likely to shape supplementation trends, highlighting the importance of understanding the potential influence of administering NAD+ on anesthetic sensitivity and recovery.
Limitations: Animal study only — human translation uncertain.
This pilot study provides critical evidence by examining peripheral endothelial function, cerebrovascular responses, and cognitive performance. Its multifaceted approach lays the groundwork for future trials to refine effect sizes and validate NR's potential to counter vascular aging and cognitive decline in PAD.
Limitations: Preliminary/pilot study — needs larger trials. No placebo control reported.
LF-NAD+, enhances the anti-aging effects of NAD+ on vascular and skin cells. Such in vitro findings might indicate a potential anti-aging role in the microcirculation and in the epidermidis.
Limitations: Animal study only — human translation uncertain.
In a "Two-hit" HFpEF mouse model, we observed increased AF susceptibility with prolonged modeling. Additionally, bioinformatics analysis and in vivo and in vitro studies highlighted progressive ZBP1-mediated PANoptosis accompanied by mitochondrial dysfunction in HFpEF atria.
Limitations: In-vitro study — may not reflect in-vivo effects.
We highlight several ongoing controversies in the field, and discuss the role of the microbiome in modulating the availability of NAD+ precursors such as nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN), the presence of multiple cellular compartments that have distinct pools of NAD+ and NADH, and non-canonical NAD+ and NADH degradation pathways. We conclude that a substantial investment in understanding the fundamental biology of NAD+, its detection and its metabolites in specific cells and cellular compartments is needed to support current translational efforts to safely boost NAD+ levels in humans.
Limitations: No placebo control reported. Review article — no new primary data.
Roles of NAD+ in Health and Aging.
Human StudyThis has led to the initiation of several clinical trials with NAD+ precursors to treat accelerated aging, age-associated dysfunctions, and diseases including Alzheimer's and Parkinson's. NAD supplementation has great future potential clinically, and these studies will also provide insight into the mechanisms of aging.
Limitations: No placebo control reported. Review article — no new primary data.
These insights suggest the need for personalized NAD + supplementation strategies, calibrated to individual patient needs and treatment timelines. Clinical trial registration jRCT1020210066.
Limitations: No placebo control reported.
Primary cilia formation requires the Leigh syndrome-associated mitochondrial protein NDUFAF2.
Human StudyThe present results provide a compelling mechanistic link, supported by evidence from human studies, between primary cilia and mitochondrial signaling. Importantly, our findings have significant implications for the development of therapeutic approaches targeting ciliopathies.
Limitations: No placebo control reported.
The Promise of Niacin in Neurology.
Human StudyFinally, we explore the proposed mechanisms through which niacin may ameliorate neuropathology. While several questions remain, the prospect of niacin as a therapeutic to alleviate neurological impairment is promising.
Limitations: No placebo control reported. Review article — no new primary data.
NAD + salvage governs mitochondrial metabolism, invigorating natural killer cell antitumor immunity.
Human StudyNAD + level was elevated in activated NK cells. NAD + supplementation not only enhanced cytokine production and cytotoxicity but also improved the proliferation and viability of NK cells.
Limitations: No placebo control reported.
Long-term NAD+ supplementation prevents the progression of age-related hearing loss in mice.
Human StudyWe also find that NR targets a novel pathway of lipid droplets in the cochlea by inducing the expression of CIDEC and PLIN1 proteins that are downstream of PPAR signaling and are key for lipid droplet growth. Taken together, our results demonstrate the therapeutic potential of NR treatment for ARHL and provide novel insights into its mechanism of action.
Limitations: No placebo control reported.
Nicotinamide Adenine Dinucleotide Supplementation in Parkinson's Disease: A Potential Disease-Modifying Agent Targeting Multiple Pathways. (Movement disorders clinical practice, 2023)
Limitations: Animal study only — human translation uncertain.
Elevated DNA damage was associated with defective DNA repair processes, including NAD-dependent parylation, in HBV-specific CD8 cells of chronic HBV patients. NAD depletion was indicated by the overexpression of CD38, the major NAD consumer, and by the significant improvement of DNA repair mechanisms, and mitochondrial and proteostasis functions by NAD supplementation, which could also improve the HBV-specific antiviral CD8 T cell function.
Limitations: No placebo control reported.
Excitingly, both adoptive CAR-T and anti-PD1 immune checkpoint blockade mouse models demonstrate that NAD+ supplementation enhanced the tumor-killing efficacy of T cells. Collectively, this study reveals that an impaired TCR-TUB-NAMPT-NAD+ axis leads to T cell dysfunction in the tumor microenvironment, and an over-the-counter nutrient supplement of NAD+ could boost T-cell-based immunotherapy.
Limitations: No placebo control reported.
Furthermore, we found that the protective effects of CD38 deficiency on VSMC senescence were related to restoration of lysosome dysfunction, particularly with respect to the maintenance of sirtuin-mediated mitochondrial homeostasis and activation of the mitochondria-lysosomal axis in VSMCs. In conclusion, our findings demonstrated that CD38 and its associated intracellular NAD decline are critical for Ang II-induced VSMC senescence and vascular remodeling.
Limitations: No placebo control reported.
This included the species Oscillospira, Butyricicoccus, Desulfovibrio, Bifidobacterium, Olsenella, Adlercreutzia, Bacteroides, Akkermansia, and Lactobacillus. Our results indicate an interplay between NR and host-microbiota in APP/PS1 mice, suggesting that the effect of NR on gut dysbiosis may be an important component in its therapeutic functions in AD.
Limitations: Animal study only — human translation uncertain.
Nicotinamide Adenine Dinucleotide in the Development and Treatment of Cardiac Remodeling and Aging.
Human StudySupplementation with NAD+ precursors or nicotinamide riboside, which enhances or supplements the NAD+metabolome, might have a protective effect on the heart. NAD+ can alleviate chronic heart failure via mitochondrial oxidation-reduction (redox) state mechanism.
Limitations: No placebo control reported.
NR treatment induced mitophagy and improved cognitive and synaptic functions in APP/PS1 mutant mice. Our findings suggest a role for NAD+ depletion-mediated activation of cGAS-STING in neuroinflammation and cellular senescence in AD.
Limitations: No placebo control reported.
In fact, different approaches to replenish or increase NAD levels have been tested, including enhancement of biosynthesis and inhibition of NAD breakdown. Despite further research is needed, this review provides an overview and update on NAD metabolism, including the therapeutic potential of its regulation, as well as pharmacokinetics, safety, precautions and formulation challenges of NAD supplementation.
Limitations: No placebo control reported. Review article — no new primary data.
NAMPT-derived NAD+ fuels PARP1 to promote skin inflammation through parthanatos cell death.
Animal StudyConsistently, an aberrant induction of NAMPT and PARP activity, together with AIFM1 nuclear translocation, was observed in lesional skin from psoriasis patients. In conclusion, hyperactivation of PARP1 in response to ROS-induced DNA damage, fueled by NAMPT-derived NAD+, mediates skin inflammation through parthanatos cell death.
Limitations: Animal study only — human translation uncertain.
Moreover, nicotinamide adenine dinucleotide, whose levels are tightly controlled by CD38, is a recognized and potent neuroprotective agent, and NAD supplementation was found to be beneficial against neurodegenerative diseases. The aims of this review are to summarize the physiological role played by CD38 in the brain, present the arguments indicating the involvement of CD38 in neurodegeneration and neuroinflammation, and to discuss these observations in light of CD38 complex biology.
Limitations: No placebo control reported. Review article — no new primary data.
Mitophagy enhancement abolishes AD-related tau hyperphosphorylation in human neuronal cells and reverses memory impairment in transgenic tau nematodes and mice. Our findings suggest that impaired removal of defective mitochondria is a pivotal event in AD pathogenesis and that mitophagy represents a potential therapeutic intervention.
Limitations: Animal study only — human translation uncertain.
Exogenous nicotinamide adenine dinucleotide regulates energy metabolism via hypothalamic connexin 43.
Animal StudyCentral and peripheral NAD administration suppressed fasting-induced hyperphagia and weight gain in mice. Extracellular NAD was imported into N1 hypothalamic neuronal cells in a connexin 43-dependent and CD73-independent manner.
Limitations: Animal study only — human translation uncertain.
For the biofilm assay, strain 719, a field isolate of A. pleuropneumoniae serovar 1, was mixed with swine isolates of Streptococcus suis, Bordetella bronchiseptica, Pasteurella multocida, Staphylococcus aureus or Escherichia coli, and deposited in 96-well microtiter plates.
Limitations: Animal study only — human translation uncertain.
Community Outcomes
Community Data Coming Soon
Aggregate community outcomes will be displayed here once we have more reports. Be one of the first to share your experience!
Outcomes are self-reported and unverified. They represent individual experiences and may not reflect typical results.
Important Warnings
- •IV infusions can cause flushing, nausea, and chest tightness
- •May cause anxiety or insomnia if taken late in day
- •Contraindicated in active cancer (theoretical concern)
- •High cost for IV therapy
Where to get NAD+, baseline labs & clinician oversight.
Ascension Peptides (US Vials)
MZ Biolabs & SafeCert COA-verified US domestic single vials with 50% off auto-applied for new customers.
SwissChems & Limitless Biotech
Same-day US domestic lyophilized vials, oral capsules, and endotoxin-screened nasal sprays (15% off Limitless w/ code PEPTIDEPROTOCOLS).
Superpower Labs & 503A Telehealth
Bloodwork, not a vial store. Get a baseline panel (100+ Quest biomarkers: metabolic, lipids, hormones, inflammation, kidney/liver) before you start a peptide protocol, then retest mid-cycle to see what actually changed.
Where to buy NAD+: best verified price
Prices checked Nov 11, 2026 · sorted by $/mg · RUO
- 1. Pure Peptides — $0.08/mg (1000mg vial, $84.00)
- 2. Direct Peptides — $0.13/mg (1000mg vial, $129.00)
- 3. Bulletproof BioLabs — $0.14/mg (500mg vial, $70.00)
Where is the cheapest place to buy NAD+?
As of Nov 11, 2026, the lowest verified US domestic single-vial price we found is Pure Peptides at $0.08/mg (1000mg vial, $84.00). We compared 10 US suppliers with live, checked prices.
How much does NAD+ cost per mg?
Verified US domestic prices currently range from $0.08/mg to $0.50/mg depending on supplier and vial size. Larger vials usually lower the $/mg.
How are these prices verified?
Each price is read from the supplier's own product page or store data and divided by the vial's mg. Suppliers we could not verify are left out rather than estimated. Tables sort strictly by $/mg, never by partner status. Prices are re-checked weekly on our price index.
Is NAD+ approved for human use?
Products from these suppliers are sold for laboratory research use only (RUO). This page is an educational price reference, not medical advice.
All compounds $/mgWeekly $/mg price indexReconstitution calculatorFree cheat sheet
Peptide Reconstitution & U-100 Syringe Cheat Sheet
Printable U-100 insulin syringe draw chart for 5mg–50mg vials, plus our weekly $/mg price-drop brief.
Related Peptides
More longevity peptides
Epitalon (Epithalon)
Epitalon is a synthetic tetrapeptide that mimics the natural...
Epithalon
The most famous Khavinson bioregulator — a synthetic tetrape...
Humanin (MDP)
Humanin is a mitochondrial-derived peptide (MDP) encoded by ...
FOXO4-DRI (Proxofim)
FOXO4-DRI is a senolytic peptide designed to selectively eli...
SS-31 (Elamipretide)
SS-31 is a mitochondria-targeted tetrapeptide that binds to ...
Popular Stacks
Vendor vs vendor: price per mg
Head-to-head $/mg on shared compounds. Prices verified Nov 11, 2026.
- Ascension vs SwissChems (3 shared compounds)
- Elite vs SwissChems (3 shared compounds)
- Elite vs Ascension (26 shared compounds)
- Protide vs SwissChems (3 shared compounds)
- Protide vs Ascension (6 shared compounds)
- Ameano vs SwissChems (3 shared compounds)
- Ameano vs Ascension (4 shared compounds)
- Swift vs Ascension (23 shared compounds)
- BioLongevity vs Ascension (16 shared compounds)
- Peptyes vs SwissChems (3 shared compounds)
- Peptyes vs Elite (20 shared compounds)
- Peptyes vs Swift (17 shared compounds)
- Peptyes vs Pure (17 shared compounds)
- Peptyes vs Ascension (20 shared compounds)
Compound vs compound: BPC-157 vs TB-500 · Tirzepatide vs Semaglutide · Retatrutide vs Tirzepatide · Wolverine Blend vs GLOW Blend · Semax vs Selank · KLOW Blend vs GLOW Blend · MOTS-c vs SS-31 · Sermorelin vs Ipamorelin · Retatrutide vs Semaglutide · Tesamorelin vs Sermorelin · All compounds $/mg →
Common questions
How many peptides are in the database?
100 compound pages, each with dosing references, reconstitution math and price per mg where a verified vendor price exists.
Where can I compare peptide prices?
Each compound page shows verified $/mg by vendor; the vendor-vs-vendor pages above compare two vendors across their shared compounds.